Haymaker, Cara

Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy

Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 1,539

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Cascone, T., William, W. N., Weissferdt, A., Leung, C. H., Lin, H. Y., Pataer, A., Godoy, M. C. B., Carter, B. W., Federico, L., Reuben, A., et al. (2021) · Nature Medicine

Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

Cited by 618

Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related Cancer: A Phase 2 Clinical Trial

Massarelli, E., William, W., Johnson, F., Kies, M., Ferrarotto, R., Guo, M., Feng, L., Lee, J. J., Tran, H., Kim, Y. U., et al. (2019) · JAMA Oncology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 490

Identification of bacteria-derived HLA-bound peptides in melanoma

Kalaora, S., Nagler, A., Nejman, D., Alon, M., Barbolin, C., Barnea, E., Ketelaars, S. L. C., Cheng, K., Vervier, K., Shental, N., et al. (2021) · Nature

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 457

Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)

Diab, A., Tannir, N. M., Bentebibel, S.-E., Hwu, P., Papadimitrakopoulou, V., Haymaker, C., Kluger, H. M., Gettinger, S. N., Sznol, M., Tykodi, S. S., et al. (2020) · Cancer Discovery

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 237

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma

Reuben, A., Spencer, C. N., Prieto, P. A., Gopalakrishnan, V., Reddy, S. M., Miller, J. P., Mao, X., De Macedo, M. P., Chen, J., Song, X., et al. (2017) · npj Genomic Medicine

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 166

Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial.

Somaiah, N., Conley, A. P., Parra, E. R., Lin, H., Amini, B., Solis Soto, L., Salazar, R., Barreto, C., Chen, H., Gite, S., et al. (2022) · The Lancet Oncology

Sarcoma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 159

Elucidation of tumor-stromal heterogeneity and the ligand-receptor interactome by single-cell transcriptomics in Real-world pancreatic cancer biopsies

Lee, J. J., Bernard, V., Semaan, A., Monberg, M. E., Huang, J., Stephens, B. M., Lin, D., Rajapakshe, K. I., Weston, B. R., Bhutani, M. S., et al. (2021) · Clinical Cancer Research

Pancreatic and Hepatic Oncology ResearchSingle-cell and spatial transcriptomics

Cited by 128

T-cell agonists in cancer immunotherapy

Choi, Y., Shi, Y., Haymaker, C. L., Naing, A., Ciliberto, G., & Hajjar, J. (2020) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 119

The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression

Huang, L., Malu, S., McKenzie, J. A., Andrews, M. C., Talukder, A. H., Tieu, T., Karpinets, T., Haymaker, C., Forget, M.-A., Williams, L. J., et al. (2018) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 102

Single-cell sequencing reveals trajectory of tumor-infiltrating lymphocyte states in pancreatic cancer

Schalck, A., Sakellariou-Thompson, D., Forget, M.-A., Sei, E., Hughes, T. G., Reuben, A., Bai, S., Hu, M., Kumar, T., Hurd, M. W., et al. (2022) · Cancer Discovery

Cancer Immunotherapy and BiomarkersPancreatic and Hepatic Oncology Research

Cited by 85

Engineered exosomes with KrasG12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates

Kalluri, V. S., Smaglo, B. G., Mahadevan, K. K., Kirtley, M. L., McAndrews, K. M., Mendt, M., Yang, S., Maldonado, A. S., Sugimoto, H., Salvatierra, M. E., et al. (2025) · Nature Communications

Extracellular vesicles in diseaseRNA Interference and Gene Delivery

Cited by 70

Loss of Rnf43 accelerates kras-mediated neoplasia and remodels the tumor immune microenvironment in pancreatic adenocarcinoma

Hosein, A. N., Dangol, G., Okumura, T., Roszik, J., Rajapakshe, K., Siemann, M., Zaid, M., Ghosh, B., Monberg, M., Guerrero, P. A., et al. (2022) · Gastroenterology

Pancreatic and Hepatic Oncology ResearchCancer Immunotherapy and Biomarkers

Cited by 61

Bintrafusp Alfa, an Anti-PD-L1:TGFβ Trap Fusion Protein, in Patients with ctDNA-positive, Liver-limited Metastatic Colorectal Cancer

Morris, V. K., Overman, M. J., Lam, M., Parseghian, C. M., Johnson, B., Dasari, A., Raghav, K., Kee, B. K., Huey, R., Wolff, R. A., et al. (2022) · Cancer Research Communications

Colorectal Cancer Treatments and StudiesCancer Immunotherapy and Biomarkers

Cited by 38

Interleukin-6 is potential target to de-couple checkpoint inhibitor-induced colitis from antitumor immunity.

Johnson, D. H., Hailemichael, Y., Foo, W. C., Hess, K. R., Haymaker, C. L., Wani, K. M., Lazar, A. J., Saberian, C. M., Bentebibel, S. E., Burton, E. M., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 9